Patents Assigned to Genentech
  • CELL CLASSIFICATION USING CENTER EMPHASIS OF A FEATURE MAP
    Publication number: 20250046063
    Abstract: Techniques described herein include, for example, generating a feature map for an input image, generating a plurality of concentric crops of the feature map, and generating an output vector that represents a characteristic of a structure depicted in a center region of the input image using the plurality of concentric crops. Generating the output vector may include, for example, aggregating sets of output features generated from the plurality of concentric crops, and several methods of aggregating are described. Applications to classification of a structure depicted in the center region of the input image are also described.
    Type: Application
    Filed: October 21, 2024
    Publication date: February 6, 2025
    Applicants: Genentech, Inc., Ventana Medical Systems, Inc., Hoffmann-La Roche Inc., Roche Molecular Systems, Inc.
    Inventors: Karol Badowski, Hartmut Koeppen, Konstanty Korski, Yao Nie
  • Imaging methods using deuterated compounds
    Patent number: 12214058
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: February 4, 2025
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Peter Williams
  • Anti-polyubiquitin multispecific antibodies
    Patent number: 12215143
    Abstract: The invention provides antibodies that bind mixed-topology polyubiquitin and multispecific anti-polyubiquitin antibodies, and methods of using the same.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: February 4, 2025
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Marissa Matsumoto, Erick Castellanos
  • METHODS OF PURIFYING POLYPEPTIDES
    Publication number: 20250034204
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Application
    Filed: October 16, 2024
    Publication date: January 30, 2025
    Applicant: Genentech, Inc.
    Inventors: Hui F. LIU, Brian David KELLEY, Deanna E. MYERS, Beth MCCOOEY, Krista Marie PETTY
  • MULTISPECIFIC ANTIGEN-BINDING PROTEINS
    Publication number: 20250032610
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Application
    Filed: June 24, 2024
    Publication date: January 30, 2025
    Applicant: Genentech, Inc.
    Inventors: Paul CARTER, Christoph SPIESS, Yiyuan YIN, Jianhui ZHOU, Wendy SANDOVAL, Jacob CORN, Michael DILLON
  • Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
    Patent number: 12209109
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 28, 2025
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda
  • Pyridine-sulfonamide derivatives as sodium channel inhibitors
    Patent number: 12209075
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. The compounds have sodium channel blocking activity that are useful for treating sodium channel-mediated diseases, in particular for treating pain.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 28, 2025
    Assignee: Genentech, Inc.
    Inventors: Steven McKerrall, Ramsay Beveridge, Kwong Wah Lai, Philippe Bergeron
  • Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
    Patent number: 12208088
    Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: January 28, 2025
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Craig Stivala, BinQing Wei, Bryan K. Chan, Timothy Heffron, Michael Lainchbury, Andrew Madin, Terry Aaron Panchal, Eileen Mary Seward, Toby Blench, Matthew W. Cartwright, Elsa Amandine Dechaux, Richard Elliott, Emanuela Gancia
  • PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS
    Publication number: 20250026810
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
    Type: Application
    Filed: May 24, 2024
    Publication date: January 23, 2025
    Applicant: Genentech, Inc.
    Inventors: Justin SCHEER, Whitney SHATZ, Domingos NG
  • Cell line development image characterization with convolutional neural networks
    Patent number: 12205386
    Abstract: A method includes, by a computing system, receiving a querying image depicting a sampling area, processing the querying image using a single cluster detection model to identify one or more regions of the querying image depicting a cluster in the sampling area, processing the one or more regions using a cluster verification deep-learning model to determine whether each depicted cluster is a cell cluster, and determining that exactly one of the identified one or more regions depicts a cluster that is a cell cluster. The method further includes processing the region depicting the cell cluster using a morphology deep-learning model to determine that there is only one cell in the cell cluster and to determine that die morphology of the cell is acceptable.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: January 21, 2025
    Assignee: Genentech, Inc.
    Inventors: Zheng Li, Mandy Man Chu Yim, Bibi Ephraim, Dat Tran, Xinyu Liu, David Shaw
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 12202824
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: January 21, 2025
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20250018032
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: September 23, 2024
    Publication date: January 16, 2025
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20250019364
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: September 12, 2024
    Publication date: January 16, 2025
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
    Publication number: 20250011474
    Abstract: The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
    Type: Application
    Filed: July 2, 2024
    Publication date: January 9, 2025
    Applicants: Genentech, Inc., Novartis AG
    Inventors: Ryan Patrick OWEN, Ahmar IQBAL, Robert A. WOOD
  • ANTIBODIES AND USES THEREOF
    Publication number: 20250011450
    Abstract: Provided herein are antibodies such as human or humanized antibodies with a modified heavy chain variable (VH) domain such that the antibodies adopt a constrained conformation (e.g., an i-shaped format) upon engaging the antigen(s) the antibodies bind to, thereby confer agonistic activities. In some cases, the antibodies are full-length antibodies (e.g., IgG antibodies). In some cases, the antibodies are monovalent antibodies (e.g., Fabs). In some cases, the antibodies target receptors which require clustering for activation (e.g., TNFR superfamily receptors). In some cases, the antibodies target two antigens on a molecule that have two or more subunits (e.g., an IL-2 receptor). Also provided herein are methods of making and using such antibodies and libraries for discovering or screening such antibodies.
    Type: Application
    Filed: June 20, 2024
    Publication date: January 9, 2025
    Applicant: Genentech, Inc.
    Inventors: Gregory Alan LAZAR, Brandon LEONARD, Matthew G. ROMEI
  • Macrocyclic compounds and methods of use thereof
    Patent number: 12187816
    Abstract: Provided, inter alia, are macrocyclic compounds.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: January 7, 2025
    Assignee: Genentech, Inc.
    Inventors: Jakob Fuhrmann, Wayne Fairbrother, Hao Wu, Jeremy Murray
  • Lactams as CBL-B inhibitors selective over C-CBL
    Patent number: 12187709
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: January 7, 2025
    Assignee: Genentech, Inc.
    Inventors: Malcolm Huestis, Michael John Lambrecht, Jun Liang, Man Un Ung, Xiaojing Wang, Jason Robert Zbieg, Bing-Yan Zhu, Lisa Marie Barton, Fabio Broccatelli, Georgette Marie Castanedo, Araz Jakalian, Robin Larouche-Gauthier, Arun Yadav
  • ANTI-KLK5 ANTIBODIES AND METHODS OF USE
    Publication number: 20250002609
    Abstract: The invention provides anti-KLK5 antibodies and methods of using the same.
    Type: Application
    Filed: June 11, 2024
    Publication date: January 2, 2025
    Applicant: Genentech, Inc.
    Inventors: Cecilia P.C. CHIU, Hilda Y. HERNANDEZ-BARRY, David B. IAEA, Moulay Hicham ALAOUI-ISMAILI, James T. KOERBER, Wei Yu LIN, Kelly LOYET, Yonglian SUN, Benjamin T. WALTERS, Jawahar SUDHAMSU
  • NANO-SUSPENSIONS AND AMORPHOUS SOLID DISPERSIONS OF HYDROPHOBIC AGENTS AND METHODS OF USE THEREOF
    Publication number: 20250000812
    Abstract: Described herein, in certain aspects, are nano-suspensions comprising a plurality of nanoparticles comprising a hydrophobic agent suspended in an aqueous carrier having a desired viscosity. In other aspects, the described herein are methods of use thereof, including methods of making a dosage form, components of the nano-suspensions, dispensing cartridges and composition therein, dosage forms, devices for dispensing a nano-suspension, and system and applications of the embodiments described herein.
    Type: Application
    Filed: September 16, 2024
    Publication date: January 2, 2025
    Applicant: Genentech, Inc.
    Inventor: Dennis Hengho LEUNG
  • SOLID FORMULATIONS COMPRISING AN INHIBITOR OF THE K-RAS PROTEIN HAVING A G12C MUTATION, AND A PROCESS FOR PREPARING
    Publication number: 20250000802
    Abstract: The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing small molecule API medicines. In some instances the API is an inhibitor of Ras proteins, such as K-Ras, H-Ras, and N-Ras, that have a G12C mutation. Such tablets also contain a disintegrant and an excipient. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing divarasib, or a pharmaceutically acceptable salt thereof, an extragranular disintegrant, and an extragranular excipient, and to processes for preparing the tablets from granules formed by dry granulation.
    Type: Application
    Filed: June 5, 2024
    Publication date: January 2, 2025
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: Samuel Hsiao-Chieh YANG, Po-Chang CHIANG, Chen MAO, Avinash MURTHY, Claudia VICENTE MARTIN